The problem in this investigation was to determine whether or not serial quantitative determinations of the circulating eosinophil leucocytes could be used as an index in following the clinical course of reactivated prostatic carcinoma. In patients that showed reactivation of their disease, the eosinophil leucocyte count average approximately one-third less than that of the patients that were controlled by anti-androgenic therapy. However, when individual counts in the two groups of patients were compared a great degree of overlap was noted; non-reactivated patients having eosinophil leucocyte counts, in many instances that were in the range of the counts observed in patients undergoing relapse. Low values were also observed in a group of clinically deteriorating patients with actively growing malignancies other than carcinoma of the prostate. Although acute adrenal hyperfunction results in a decrease in the number of circulating eosinophils, it is felt by most investigators at the present time that the absolute level of eosinophil leucocytes in the blood at any given time does not accurately reflect the state of adrenal cortical activity. If the suggestive depression of the eosinophil count in patients with reactivated carcinoma of the prostate is significant, it may indicate only an adrenal response to "non-specific" stress rather than being a specific measure of adrenal hyperactivity with resultant androgen stimulus to the tumor. From the results of this study it would seem that the eosinophil leucocyte count cannot be used in following the clinical course of reactivated prostatic carcinoma patients.
Atkins, Dale Morrell, "A Quantitative Determination of Eosinophil Leucocytes in Patients With Carcinoma of the Prostate: A Review of Endocrine Factors Associated with Carcinoma of the Prostate" (1953). University Libraries Digitized Theses 189x-20xx. 61.